Lunit to Partner With U.S. Discovery, Offer Lunit SCOPE Analysis to Global Pharma
TECHWORLD · · 2 views
✦ AI Summary
Lunit announced that it will provide AI pathology analysis services to global pharmaceutical companies in partnership with Discovery Life Sciences.
Lunit SCOPE will be used alongside Discovery's work in biomarker and tissue analysis tasks commissioned by global pharmaceutical companies.
The two companies plan to provide AI pathology analysis tailored to client needs and expand the application of related services throughout the drug development process.
Lunit announced on the 12th that it will provide AI pathology analysis services to global pharmaceutical companies in partnership with Discovery Life Sciences. Under the partnership, Lunit SCOPE will be used alongside Discovery's work in biomarker and tissue analysis tasks commissioned by global pharma companies.
Based on this, the two companies plan to provide AI pathology analysis tailored to client needs. They also plan to expand the application of related services throughout the drug development process.
Discovery is headquartered in Huntsville, Alabama, and is a bio-samples and analysis company. Lunit said Discovery has continued its bio-testing business for more than 25 years, supported more than 2,000 clinical trial programs, and is currently supporting more than 350 clinical trials.
Discovery provides testing services related to the entire drug development process, with service areas including sample supply, molecular pathology, genomics analysis, and proteomics analysis. Lunit plans to combine this with AI-based tissue analysis technology, aiming to provide biomarker data that pharmaceutical companies and research institutions can use.
Lunit plans to take part on the 14th local time in Discovery's 'B4 Tour (Bridging Biomarker Breakthroughs to Bedsides)' in South San Francisco, California. Lunit Medical Director Im Yu-ju is scheduled to speak in an expert session and will also join a panel discussion on 'The Present and Future of AI Biomarkers.' The event is aimed at representatives and researchers from global pharmaceutical companies that have worked with Discovery, and Lunit plans to introduce how Lunit SCOPE can be used during the event.
Through this partnership, Lunit plans to expand the scope of AI pathology analysis. The company plans to broaden its application into precision medicine areas such as drug candidate development and clinical trials.
Lunit CEO Seo Beom-seok cited rising demand for quantitative and reproducible biomarker discovery in the drug development process as the background for pursuing the partnership with Discovery, and said the company will use the collaboration to push more global companies and researchers to use Lunit SCOPE.
Anna Juncker-Jensen, head of Discovery's science division, emphasized consistency in tissue sample and processing procedures as a key element of AI pathology analysis, and explained plans to combine Lunit SCOPE with Discovery's in-house capabilities in sample acquisition, tissue processing, and pathology analysis to provide data that partner companies can use.
Source: TECHWORLD · Kim Seung-ki
Original: https://www.epnc.co.kr/news/articleView.html?idxno=408013
References
This article was produced with the help of an automated content generation algorithm.
Source: TECHWORLD
View originalThis article was summarized and organized by BizCrush based on the original article from TECHWORLD. For exact quotations and full details, please refer to the original article.